Bausch Health Companies BHC Bausch + Lomb — Operating Income (Loss)

Other segment segments

Similar metrics at other companies

DHRLife Sciences — Operating Income (Loss)

$225M+11.9%

TMOLaboratory Products and Biopharma Services — Operating Income (Loss)

$778M+6.4%

SHLSEBOS Solutions and Components — Operating Income (Loss)

$7.72M+79.0%

BCCorporate Segment — Operating Income (Loss)

-$41.3M-22.2%

TMOLife Sciences Solutions — Operating Income (Loss)

$954M+14.4%

DGXAll other operating segments — Operating Income (Loss)

$7M-12.5%

Questions, answered.

What is Bausch Health Companies's bausch + lomb — operating income (loss)?

Bausch Health Companies (BHC) reported bausch + lomb — operating income (loss) of $277M in Q1 2026.

How has Bausch Health Companies's bausch + lomb — operating income (loss) changed year-over-year?

Bausch Health Companies's bausch + lomb — operating income (loss) increased by 53.9% year-over-year, from $180M to $277M.

What is the long-term trend for Bausch Health Companies's bausch + lomb — operating income (loss)?

Over 4 years (2021 to 2025), Bausch Health Companies's bausch + lomb — operating income (loss) has grown at a 4.1% compound annual growth rate (CAGR), from $958M to $1.13B.

What does bausch + lomb — operating income (loss) mean?

Measures the profitability of the Bausch + Lomb segment by subtracting operating expenses from total segment revenues. It provides a clear view of the segment's core operational performance before accounting for interest, taxes, and corporate-level financial decisions.